Medtronic plc (MDT)
86.07 USD -6.74 (-7.26%) Volume: 14.34M
Medtronic plc’s stock price stands at 86.07 USD, experiencing a significant drop of 7.26% in this trading session with a trading volume of 14.34M, yet showcasing a positive YTD performance with a percentage change of +7.75%, indicating a resilient market presence.
Latest developments on Medtronic plc
Medtronic Plc has been experiencing fluctuations in its stock price following the release of its third quarter fiscal 2025 financial results. Despite reporting a profit that surpassed analyst estimates, the company expects pressure in its surgical unit for the fourth quarter, causing shares to fall. The growth in heart surgery devices has been credited for the profit increase, while the diabetes device sales have also contributed positively. However, the surgical unit’s performance has lagged behind, leading to a slip in the stock price after a revenue miss in the third quarter. Medtronic remains optimistic about its annual forecast and is nearing FDA submission for its Hugo robot. The company’s stock movements are closely tied to its financial performance and market expectations, with analysts closely monitoring its earnings reports and revenue projections.
Medtronic plc on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely monitoring Medtronic Plc‘s performance. In their recent report titled “Medtronic plc: Are Its Investments in Robotics with Hugo Robotic-Assisted Surgery System Yielding Results? – Major Drivers,” they highlighted the company’s fiscal 2025 first-quarter results. The report emphasized Medtronic’s sustained performance trajectory, with key financial metrics meeting or exceeding expectations. Revenue growth of 5.3% was reported, driven by strong performances in the Cardiovascular, Neuroscience, and Diabetes segments.
The analysts at Baptista Research, known for their bullish lean, also noted the continued growth across Medtronic’s business segments. They highlighted strategic advancements in product innovations and global market expansions as key drivers of the company’s success. Investors and stakeholders can find more detailed insights on Medtronic Plc‘s performance on Smartkarma’s platform under the entity profile for Medtronic Plc.
A look at Medtronic plc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Medtronic Plc, a company that develops medical products, has received favorable scores in the areas of Dividend and Momentum according to Smartkarma Smart Scores. With a strong Dividend score of 4, investors can expect consistent dividend payouts from the company. Additionally, a Momentum score of 4 indicates that the company is experiencing positive upward trends that may lead to future growth opportunities.
Looking ahead, Medtronic Plc also shows promising scores in the areas of Value, Growth, and Resilience, with scores of 3 for each. This suggests that the company is positioned well for long-term success, with a focus on delivering value to investors, maintaining steady growth, and demonstrating resilience in the face of challenges. Overall, Medtronic Plc‘s Smartkarma Smart Scores paint a positive outlook for the company’s future prospects in the medical products industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
